- Home
- VTYX vs IPHA Comparison
VTYX vs IPHA Comparison
Compare VTYX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- IPHA
- Stock Information
- Founded
- VTYX 2018
- IPHA 1999
- Country
- VTYX United States
- IPHA France
- Employees
- VTYX N/A
- IPHA N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- IPHA Health Care
- Exchange
- VTYX Nasdaq
- IPHA Nasdaq
- Market Cap
- VTYX 154.9M
- IPHA 160.1M
- IPO Year
- VTYX 2021
- IPHA 2019
- Fundamental
- Price
- VTYX $1.28
- IPHA $2.20
- Analyst Decision
- VTYX Buy
- IPHA Strong Buy
- Analyst Count
- VTYX 4
- IPHA 1
- Target Price
- VTYX $11.33
- IPHA $11.00
- AVG Volume (30 Days)
- VTYX 1.3M
- IPHA 29.4K
- Earning Date
- VTYX 05-08-2025
- IPHA 03-27-2025
- Dividend Yield
- VTYX N/A
- IPHA N/A
- EPS Growth
- VTYX N/A
- IPHA N/A
- EPS
- VTYX N/A
- IPHA N/A
- Revenue
- VTYX N/A
- IPHA $20,831,349.00
- Revenue This Year
- VTYX N/A
- IPHA $209.83
- Revenue Next Year
- VTYX N/A
- IPHA $83.96
- P/E Ratio
- VTYX N/A
- IPHA N/A
- Revenue Growth
- VTYX N/A
- IPHA N/A
- 52 Week Low
- VTYX $0.78
- IPHA $1.29
- 52 Week High
- VTYX $5.66
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- VTYX 56.45
- IPHA 68.86
- Support Level
- VTYX $1.14
- IPHA $1.84
- Resistance Level
- VTYX $1.32
- IPHA $2.19
- Average True Range (ATR)
- VTYX 0.09
- IPHA 0.11
- MACD
- VTYX 0.04
- IPHA 0.04
- Stochastic Oscillator
- VTYX 90.22
- IPHA 100.00
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.